Cargando…

Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial

INTRODUCTION: Non-cystic fibrosis bronchiectasis (NCFB) brought a heavy healthcare burden worldwide. Macrolide maintenance therapy was proved to be helpful in reducing exacerbation of NCFB. However, the optimal dosing regimens of macrolides have not been determined, and its efficacy in Chinese NCFB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Yanxiong, Chen, Lan, He, Ting, Li, Jing, Zou, Aiping, Li, Feng, Chen, Fei, Fan, Bo, Ni, Weihao, Xiao, Wei, You, Huimin, Fu, Wenjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Respiratory Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272127/ https://www.ncbi.nlm.nih.gov/pubmed/35803624 http://dx.doi.org/10.1136/bmjopen-2021-059186

Ejemplares similares

Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study
por: Wang, Hong, et al.
Publicado: (2018)

KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea
por: Lee, Hyun, et al.
Publicado: (2020)

Observational study of sleep, respiratory mechanics and quality of life in patients with non-cystic fibrosis bronchiectasis: a protocol study
por: Faria Júnior, Newton Santos, et al.
Publicado: (2015)

Efficacy of N-acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol
por: Luo, Ai, et al.
Publicado: (2022)

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021: a systematic review and meta-analysis
por: Zhou, Yunchun, et al.
Publicado: (2022)

Utility of a personalised Bronchiectasis Action Management Plan (BAMP) for children with bronchiectasis: protocol for a multicentre, double-blind parallel, superiority randomised controlled trial
por: Marchant, Julie M, et al.
Publicado: (2021)

A smartphone application for reporting symptoms in adults with cystic fibrosis: protocol of a randomised controlled trial
por: Wood, Jamie, et al.
Publicado: (2018)

Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis
por: Morton, Miranda, et al.
Publicado: (2023)

Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa
por: Singh, Jagdev, et al.
Publicado: (2023)

Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants
por: Lowe, John, et al.
Publicado: (2020)

Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis
por: He, Min, et al.
Publicado: (2020)

The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies
por: Li, Kui, et al.
Publicado: (2022)

Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison
por: Li, Wen, et al.
Publicado: (2018)

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
por: Lötvall, J, et al.
Publicado: (2012)

Bronchiectasis and the risk of cardiovascular disease: a population-based study
por: Navaratnam, Vidya, et al.
Publicado: (2017)

Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts
por: McDonnell, M J, et al.
Publicado: (2016)

Rationale for azithromycin in COVID-19: an overview of existing evidence
por: Gyselinck, Iwein, et al.
Publicado: (2021)

A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis
por: Ratnayake, Irushi, et al.
Publicado: (2020)

Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis
por: Abbott, Janice, et al.
Publicado: (2015)

Survey of exercise testing and training in cystic fibrosis clinics in the UK: a decade of progress
por: Tomlinson, Owen William, et al.
Publicado: (2023)

Global impact of bronchiectasis and cystic fibrosis
por: Redondo, Margarida, et al.
Publicado: (2016)

Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations
por: O'Reilly, Philip J, et al.
Publicado: (2013)

Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation
por: Hind, Daniel, et al.
Publicado: (2020)

Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Moustaki, Maria, et al.
Publicado: (2017)

The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Cuthbertson, Leah, et al.
Publicado: (2021)

Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis
por: McLeod, Charlie, et al.
Publicado: (2022)

Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis
por: Liu, Wei, et al.
Publicado: (2020)

Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol
por: Nakagawa, Taku, et al.
Publicado: (2019)

Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis
por: Dmello, Dayton, et al.
Publicado: (2011)

Azithromycin and the microbiota of cystic fibrosis sputum
por: Acosta, Nicole, et al.
Publicado: (2021)

Survey-identified experiences of prediagnosis and diagnosis process among patients with COPD, asthma, interstitial lung disease and bronchiectasis
por: Zhang, Xiubin, et al.
Publicado: (2023)

Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study
por: Palser, Sally C, et al.
Publicado: (2016)

Cystic fibrosis modulator therapy can reverse cystic bronchiectasis
por: Middleton, Peter G., et al.
Publicado: (2023)

Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Bergin, David A, et al.
Publicado: (2013)

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Alyasin, Soheila, et al.
Publicado: (2018)

Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis
por: Bar-Yoseph, Ronen, et al.
Publicado: (2019)

Bordetella bronchiseptica in non-cystic fibrosis bronchiectasis
por: Karamooz, Elham, et al.
Publicado: (2018)

Brazilian consensus on non-cystic fibrosis bronchiectasis
por: Pereira, Mônica Corso, et al.
Publicado: (2019)

Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey
por: Wagner, Dirk, et al.
Publicado: (2020)

Changes in Clinical Markers During A Short-Term Transfer Program of Adult Cystic Fibrosis Patients from Pediatric to Adult Care
por: Welsner, Matthias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_81674tm0mvvl0uqovjd93tocjl